The antimalarial agent mefloquine inhibits ATP-sensitive K-channels

British Journal of Pharmacology

Volumn 131, Issue 4, 2000, Pages 756-760

  Gribble, Fiona M ^a   Davis, Timothy M E ^b   Higham, Claire E ^a   Clark, Anne ^a   Ashcroft, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antimalarial agents; Artenusate; K(ATP) channel; Malaria; Mefloquine; Potassium channel

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; CHLOROQUINE; LARIUM; MEFLOQUINE; POTASSIUM CHANNEL; QUININE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME SUBUNIT; FEMALE; HEART MUSCLE CONDUCTION DISTURBANCE; INSULIN RELEASE; MENTAL DISEASE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PANCREAS ISLET BETA CELL; POTASSIUM CONDUCTANCE; PRIORITY JOURNAL; RAT; XENOPUS LAEVIS;

EID: 0035230615     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703638     Document Type: Article

References (35)

1. AGUILAR-BRYAN, L., NICHOLS, C.G., WECHSLER, S.W., CLEMENT, J.P., BOYD, A.E., GONZALEZ, G., HERRERA-SOSA, H., NGUY, K., BRYAN, J. & NELSON, D.A. (1995). Cloning of the β-cell high-affinity sulphonylurea receptor: a regulator of insulin secretion. Science, 268, 423-425.
2. ASHCROFT, F.M. & ASHCROFT, S.J.H. (1992). The sulphonylurea receptor. Biochim. Biophys. Acta, 1175, 45-59.
3. + channels. Trends Neurosci., 21, 288-294.
4. + channels in health and disease. Diabelologia, 42, 903-919.
5. ASHCROFT, F.M. & RORSMAN, P. (1989). Electrophysiology of the pancreatic β-cell. Prog. Biophys. Mol. Biol.. 54, 87-143.
6. ASSAN, R., PERRONNE, C., CHOTARD, L., LARGER, E. & VILDE, J.L. (1995). Mefloquine-associated hypoglycaeraia in a cachectic AIDS patient. Diabete Metab., 21, 54-58.
7. BATEMAN, D.N. & DYSON, E.H. (1996). Quinine toxicity. Adverse Drug React. Acute Poison Rev., 4, 215-233.
8. BATTY, K.T., THU, L.T., DAVIS, T.M., MAI, T.X., HUNG, N.C., TIEN, N.P., POWELL, S.M., THIEN, H.V., BINH, T.Q. & KIM, N.V. (1998). A pharmacokinetic and pharmadynamic study of intravenous vs oral artensunate in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol., 45, 123-129.
9. BEM, J.L., KERR, L. & STURCHLER, D. (1992). Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J. Trop. Med. Hyg., 95, 167-179.
10. BHATIA, M.S. (1991). Chloroquine-induced psychiatric complications. Br. J. Psych.. 159, 735.
11. BLACKSHEAR, P.J., HOLLOWAY, A.H. & ALBERTI, K.G.M.M. (1975). The effects of inhibition of gluconeogenesis on ketogenesis in starved and diabetic rats. Biochem. J., 148, 353-362.
12. + channels in mouse pancreatic β-cells by external tetraethylammonium ions and quinine. J. Physiol., 423, 311-325.
13. BREWER, T.G., GRATE, S.J., PEGGINS, J.O., WEINA, P.J., PETRAS, J.M., LEVINE, B.S., HEIFFER, M.H. & SHUSTER, B.G.. (1994). Fatal neurotoxicity of arteether and artemether. Am. J. Trop. Med. Hyg., 51, 251-259.
14. ATP channel subunits. Neuron. 18, 827-838.
15. DAVIS, T.M.E. (1997). Antimalarial drugs and glucose metabolism. Br. J. Clin. Pharmacol., 44, 1-7.
16. DAVIS, T.M.E., DEMBO, L.G., KAYE-EDDIE, S.A., HEWITT, B.J., HISLOP, R.G. & BATTY, K.T. (1997). Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br. J. Clin. Pharmacol., 43, 665.
17. DAVIS, T.M.E., SUPANARANOND, W., PUKRITTAYAKAMEE, S., KARBWANG, J., MOLUNTO, P., MEKTHON, S. & WHITE, N. (1990). A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. J. Infect. Dis., 161, 1305-1308.
18. EDWARDS, G. & WESTON, A.H. (1993). The pharmacology of ATP-sensitive potassium channels. Ann. Rev. Pharm. Toxicol., 33, 597-637.
19. FOLEY, M. & TILLEY, L. (1997). Quinoline antimalarials: mechanisms of action and resistance. Int. J. Parasitol., 27, 231-240.
20. GRIBBLE, F.M., ASHFIELD, R., AMMALA, C. & ASHCROFT, F.M. (1997). Properties of cloned ATP-sensitive K-currents expressed in Xenopus oocytes. J. Physiol., 498.1, 87-98.
21. HIEN, T.T. & WHITE, N.J. (1993). Qinghaosu. Lancet, 341, 603-608.
22. KATP: an inward rectifier subunit plus the sulphonylurea receptor. Science, 270, 1166-1169.
23. + channels. Neuron, 16, 1011-1017.
24. + channel. J. Biol. Chem., 271, 24321-24325.
25. JASPERS, C.A., HOPPERUS BUMA, A.P., VAN THIEL, P.P., VAN HULST, R.A. & KAGER, P.A. (1996). Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am. J. Trop. Med.Hyg., 55, 230-234.
26. ATP channel formation by the sulphonylurea receptor SUR1 with Kir6.2 subunits in rat dorsal vagal neurons in situ. J. Physiol., 509.2, 339-346.
27. LISS, B., BRUNS, R. & ROEPER, J. (1999). Alternative sulphonylurea receptor expression defines metabolic sensitivity of K-ATP channels in dopaminergic midbrain neurones. EMBO J., 18, 833-884.
28. NICHOLS, C.G. & LEDERER, W.J. (1991). Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am. J. Physiol., 261, H1675-H1686.
29. NOSTEN, F., TER KUILE, F.O., LUXEMBURGER, C., WOODROW, C., KYLE, D.E., CHONGSUPH AJAISIDDHI, T. & WHITE, N.J. (1993). Cardiac effects of antimalarial treatment with halofantrine. Lancet, 341, 1054-1056.
30. PALMER, K.J., HOLLIDAY, S.M. & BROGDEN, R.N. (1993). Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 45, 430-475.
31. ATP channels is mediated by Kir6.2. Proc. Nat. Acad. Sci., 94, 11716-11720.
32. SAKURA, H., AMMALA, C., SMITH, P.A., GRIBBLE, F.M. & ASHCROFT, F.M. (1995). Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel expressed in pancreatic β-celss, brain, heart and skeletal muscle. FEBS Lett., 377, 338-344.
33. SHEINER, L.B., STANSKI, D.R., VOZEH, S., MILLER, R.D. & HAM, J. (1979). Simultaneous modelling of pharmacokinetics and pharmacodynamics: applications to d-tubocurarine. Clin. Pharmac. Ther., 25, 358-371.
34. TUCKER, S.J., CRIBBLE, F.M., ZHAO, C., TRAPP, S., ASHCROFT, F.M. (1997). Truncation of Kir6.2 produces ATP-sensitive K-channels in the absence of the sulphonylurea receptor. Nature, 387, 179-183.
35. WORLD HEALTH ORGANIZATION. (1996). Mefloquine: update on safety issues. WHO Drug Info., 10, 58-61.